Skip to main content
SpringerLink
Log in

lnterleukin-2 receptor antibodies for cardiac allograft

  • Chapter
Thorakale Organtransplantation

  • 24 Accesses

Zusammenfassung

Rejection involves cell- and antibody-mediated organ injury occurring as the result of recognition of an allograft as nonself. This process is categorized histologically and immunologically into three major types: hyperacute, acute and chronic. Hyperacute rejection is mediated by pre-existing antibodies to allogeneic antigens on the vascular endothelial cells within the donor organ. Donor recipient human leukocyte antigen (HLA) and ABO blood-group cross-matching are used to prevent hyperacute rejection [2]. Acute rejection is primarily a cell-mediated process that most commonly occurs from the first week to several years after transplantation. After heart transplantation [24], 61% of patients remain rejection free after the first posttransplantation month, 38% of patients are without rejection by 6 months, and 34% of patients are without rejection by 2 months. The hazard function for initial rejection peaks at approximately 1 month. Chronic rejection, or late graft failure, is an irreversible gradual deterioration of graft function that occurs in many allografts months to years after transplantation as the result of intimal thickening and fibrosis [2]. Cardiac allograft vasculopathy is angiographically evident in ≤45% of heart transplant recipients who survive ≥3 years [39]. This form of rejection involves a variety of immunesystem components: T cells, cytokines, macrophages, and adhesion molecules [3].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 44.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abbas AK, Lichtman AH, Pober JS (1994) Cytokines. In: Cellular and Molecular Immunology. 2nd ed. WB Saunders, Philadelphia, PA, S239-S260

    Google Scholar 

  2. Abbas AK, Lichtman AH, Pober JS (1994) Immune responses to tissue transplants. In: Cellular and Molecular Immunology. WB Saunders, Philadelphia, PA, S335–S337

    Google Scholar 

  3. Azuma H, Tilney NL (1994) Chronic graft rejection. Curr Opin Immunol 6:770–776

    Article  PubMed  CAS  Google Scholar 

  4. Baan CC, van Gelder T, Balk AHMM et al (2000) Functional responses of T cells blocked by anti-CD25 antibody therapy during cardiac rejection. Transplantation 69:331–336

    Article  PubMed  CAS  Google Scholar 

  5. Baan CC, Knoop CJ, van Gelder T et al (1999) Anti-CD25 therapy reveals the redudancy of the intragraft cytokine network after clinical heart transplantation. Transplantation 67:870–876

    Article  PubMed  CAS  Google Scholar 

  6. Beniaminovitz A, Itescu S, Lietz K et al (2000) Prevention of rejection in cardiac transplantation by blockade of interleukin-2 receptor with a monoclonal antibody. N Engl J Med 342:613–619

    Article  PubMed  CAS  Google Scholar 

  7. Billingham R, Brent L, Medawar P (1956) Quantitative studies on tissue transplantation immunity III. Actively acquired tolerance. Proc R Soc Lond [Biol] 238:357–415

    Google Scholar 

  8. Bonnefoy-Berard N, Verrier B, Vincent C et al (1992) Inhibition of CD25 (IL-2Ra) expression and T-cell proliferation by polyclonal anti-thymocyte globulin. Immunology 77:61–67

    PubMed  CAS  Google Scholar 

  9. Bristow MR, Gilbert EM, Renlund DG et al (1988) Use of OKT3 monoclonal antibody in heart transplantation: review of the initial experience. J Heart Transplant 1:11

    Google Scholar 

  10. Burdick JF (1992) Biology of immunosuppresion mediated by antilymphocyte antibodies. In: Burdick JF, Racusen LC, Solez K et al, eds. Kidney Transplant Rejection. Diagnosis and Treatment. 2nd ed. Marcel Dekker, New York, S505-S539

    Google Scholar 

  11. Costanzo-Nordin MR (1992) Cardiac allograft vasculopathy: relationship with acute cellular rejection and histocompatibility. J Heart Lung Transplant 11:S90–S103

    PubMed  CAS  Google Scholar 

  12. Debure A, Chkoff N, Chatenoud L et al (1988) One-month prophylactic use of OKT3 in cadaver kidney transplant recipients. Transplantation 45:546–553

    Article  PubMed  CAS  Google Scholar 

  13. Evans RW, Manninen DL, Dong FB et al (1993) Immunosuppressive therapy as a determinant of transplantation outcomes. Transplantation 55:1297–1305

    Article  PubMed  CAS  Google Scholar 

  14. Gaston R, Deierhoe M, Ayres I (1995) HLA matching in renal transplantation. N Engl J Med 332:752–753

    Article  PubMed  CAS  Google Scholar 

  15. Gilbert EM, DeWitt CW, Eisworth CC et al (1982) Treatment of refractory cardiac allograft rejection with OKT3 monoclonal antibody. Am J Med 82: 202–206

    Article  Google Scholar 

  16. Halloran PF, Broski AP, Batiuk TD et al (1993) The molecular immunology of acute rejection: an overview. Transplant Immunol 1:3–27

    Article  CAS  Google Scholar 

  17. Hammond EH, Yowell RL, Price GD et al (1992) Vascular rejection and its relationship to allograft coronary artery disease. J Heart Lung Transplant 11:S111–S119

    PubMed  CAS  Google Scholar 

  18. Johnson MR, Mullen GM, O’Sullivan EJ et al (1994) Risk/benefit ratio of perioperative OKT3 in cardiac transplantation. Am J Cardiol 74:261–266

    Article  PubMed  CAS  Google Scholar 

  19. Jones PT, Dear PH, Foote J et al (1986) Replacing the complementarity-determining regions in a human antibody with those from a mouse 321:522–525

    CAS  Google Scholar 

  20. Kirkman R, Shapiro M, Carpentier C et al (1991) A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. Transplantation 51:107–113

    Article  PubMed  CAS  Google Scholar 

  21. Klein J, Takahata N, Ayala FJ (1993) MHC polymorphism and human origins. Sci Amer 269:78–83

    Article  PubMed  CAS  Google Scholar 

  22. Kobashigawa J, Miller L, Renlund D et al (1998) A randomized active controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 66:507–515

    Article  PubMed  CAS  Google Scholar 

  23. Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495

    Article  PubMed  CAS  Google Scholar 

  24. Kubo SH, Naftel DC, Mills RM et al (1995) Risk factors for late recurrent rejection after heart transplantation: a multiinstitutional, multivariable analysis. J Heart Lung Transplant 14:409–418

    PubMed  CAS  Google Scholar 

  25. Lazarovits AI, Rochon J, Banks L et al (1993) Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection. J Immunol 150:5163–5174

    PubMed  CAS  Google Scholar 

  26. Lenschow DJ, Walunas TL, Bluestone JA (1996) CD28/B7 system of T-cell costimulation. Annu Rev Immunol 14:233–258

    Article  PubMed  CAS  Google Scholar 

  27. Male D, Champion B, Cooke A et al (1991) Advanced Immunology. 2nd ed. JB Lippincott, Philadelphia

    Google Scholar 

  28. Nair RV, Morris RE (1995) Immunosuppression in cardiac transplantation: a new era in immunopharmacology. Curr Opin Cardio 10:210–217

    Google Scholar 

  29. Nashan B, Moore R, Amlot P et al (1997) Randomized trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 350:1193–1198

    Article  PubMed  CAS  Google Scholar 

  30. Reichmann K, Clark M, Waldmann H et al (1988) Reshaping human antibodies for therapy. Nature 332:323–327

    Article  Google Scholar 

  31. Sommer BG, Henry ML, Ferguson RM (1987) Sequential antilymphoblast gobulin and cyclosporin for renal transplantation. Transplantation 43:85–90

    Article  PubMed  CAS  Google Scholar 

  32. Steinmuller DR, Hodge E, Boshkos C et al (1991) Prophylaxis and treatment of post-renal transplant rejection. Clev Clin J Med 58:125–130

    CAS  Google Scholar 

  33. Stock PG, Lantz, Light S (1996) In vivo (phase I) trial and in vitro efficacy of humanized anti-Tac for the prevention of rejection in renal transplant recipients. Transplant Proc 28:915–916

    PubMed  CAS  Google Scholar 

  34. Soulilou JP (1994) Relevant targets for therapy with monoclonal antibodies in allograft transplantation. Kidney Int 46:540–553

    Article  Google Scholar 

  35. Soulilou J, Cantrarovich D, Le Mauff B et al (1990) Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33b3.1) as compared with rabbit antithymocyte globulin for the prophylaxis against rejection of renal allografts. N Engl J Med 32:1175–1182

    Article  Google Scholar 

  36. Swinnen LJ, Costanzo-Nordin MR, Fisher SG et al (1990) Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med 323:1723–1728

    Article  PubMed  CAS  Google Scholar 

  37. Transy C, Moingeon PE, Marshall B et al (1989) Most anti-human CD3 monoclonal antibodies are directed to the CD3 ε subunit. Eur J Immunol 19:947–950

    Article  PubMed  CAS  Google Scholar 

  38. Unanue ER (1993) Macrophages, antigen-presenting cells, and the phenomena of antigen handling and presentation. In: Paul WE, ed. Fundamental Immunology. 3rd ed. Raven Press, New York, S111–S114

    Google Scholar 

  39. Uretsky BF, Murali S, Reddy PS et al (1987) Development of coronary artery disease in cardiac transplant recipients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation 76:827–834

    Article  PubMed  CAS  Google Scholar 

  40. van Gelder T, Baan CC, Balk AHMM et al (1998) Blockade of the interleukin IL-2/IL2 receptor pathway with a monoclonal anti-IL2-2 receptor antibody (BT563) does not prevent the development of acute heart allograft rejection in humans. Transplantation 65:405

    Article  PubMed  Google Scholar 

  41. van Gelder T, Balk AHMM, Jonkam FAM et al (1996) A randomized trial comparing safety and efficacy of OKT3 and a monoclaonal anti-interleukin-2 receptor antibody (BT563) in the prevention of acute rejection after heart transplantation. Transplantation 62:51

    Article  PubMed  Google Scholar 

  42. Ventura HO, Mehra MR, Smart FW, Stapleton DD (1995) Cardiac allograft vasculopathy: current concepts. Am Heart J 129:791–798

    Article  PubMed  CAS  Google Scholar 

  43. Vincenti F, Kirkman R, Light S et al (1998) Interleukin-2 receptor blockade via daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 338:161–165

    Article  PubMed  CAS  Google Scholar 

  44. Waldman TA (1993) 1992 Stohlman memorial lecture: targeting the IL-2 receptor. Leukemia 7(suppl2), S151–S156

    Google Scholar 

  45. Weiss A, Littman DR (1994) Signal transduction by lymphocyte antigen receptors. Cell 76:263–274

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. X. M. Mueller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Seydoux
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Tevaearai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. Tinguely
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. J. Goy
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F. Stumpe
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. L. K. von Segesser
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Universitätsklinik für Herz- und Thoraxchirurgie Kantonsspital Basel, Spitalstraße 21, CH-4031, Basel, Switzerland

    Florian Rüter , Peter Buser  & Hans-Reinhard Zerkowski ,  & 

  2. I. Medizinische Klinik Klinikum Augsburg, Stenglinstraße 2, 86156, Augsburg, Germany

    Wolfgang von Scheidt

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Mueller, X.M. et al. (2002). lnterleukin-2 receptor antibodies for cardiac allograft. In: Rüter, F., von Scheidt, W., Buser, P., Zerkowski, HR. (eds) Thorakale Organtransplantation. Steinkopff, Heidelberg. https://doi.org/10.1007/978-3-642-57513-6_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-57513-6_8

  • Publisher Name: Steinkopff, Heidelberg

  • Print ISBN: 978-3-7985-1350-1

  • Online ISBN: 978-3-642-57513-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation